Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Enveric Biosciences, Inc. (ENVB)

1.3700 0.0000 (0.00%)
At close: August 31 at 4:00:01 PM EDT
1.3500 -0.0200 (-1.46%)
Pre-Market: 8:30:51 AM EDT
Chart Range Bar
Loading chart for ENVB
  • Previous Close 1.3700
  • Open 1.3757
  • Bid 1.0100 x 200
  • Ask 1.7200 x 200
  • Day's Range 1.3300 - 1.3800
  • 52 Week Range 1.1700 - 13.6320
  • Volume 38,279
  • Avg. Volume 157,968
  • Market Cap (intraday) 6.132M
  • Beta (5Y Monthly) 1.11
  • PE Ratio (TTM) --
  • EPS (TTM) -12.1800
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Apr 23, 2008
  • 1y Target Est --

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

www.enveric.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 8/31/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ENVB
62.26%
S&P 500 (^GSPC)
12.28%

1-Year Return

ENVB
89.90%
S&P 500 (^GSPC)
18.98%

3-Year Return

ENVB
99.98%
S&P 500 (^GSPC)
70.51%

5-Year Return

ENVB
100.00%
S&P 500 (^GSPC)
69.95%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY24
Revenue --
Earnings -3.15M
Profit Margin 0.00%

Q1

FY24

Q2

FY24

Q3

FY24

Q4

FY24

-3M
-2M
-1M
0
0.0%

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    6.13M

  • Enterprise Value

    -2.16M

  • Trailing P/E

    0.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.76

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -87.34%

  • Return on Equity (ttm)

    -170.04%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -12.09M

  • Diluted EPS (ttm)

    -12.1800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.3M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.2M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.3700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: